Roche Drug Poised to Revolutionize Rare Kidney Disease Treatment

BASEL, SWITZERLAND – February 16, 2026 – Pharmaceutical giant Roche announced today what could be a turning point for thousands living with a rare and debilitating autoimmune kidney disease. The company's drug, Gazyva/Gazyvaro (obinutuzumab), met all primary goals in a landmark Phase III trial, demonstrating a significant ability to put primary membranous nephropathy (PMN) into complete remission and potentially becoming the first-ever therapy specifically approved for the condition.

The results from the global MAJESTY study showed that Gazyva/Gazyvaro was statistically and clinically superior to tacrolimus, a current standard-of-care immunosuppressant, in achieving complete remission at two years. This breakthrough offers a beacon of hope for a patient population that has long navigated a landscape of limited and often harsh treatment options.

“These results demonstrate that Gazyva/Gazyvaro may help more people with primary membranous nephropathy achieve complete remission, maintain kidney function for longer and delay or potentially prevent the onset of life-threatening complications,” said Levi Garraway, M.D., PhD, Roche’s Chief Medical Officer and Head of Global Product Development, in a statement. “If approved, Gazyva/Gazyvaro would be the first therapy specifically indicated for people with primary membranous nephropathy.”

The Human Cost of a Hidden Disease

Primary membranous nephropathy is a chronic condition where the body's own immune system mistakenly attacks the glomeruli, the tiny filtering units of the kidneys. This assault causes large amounts of protein to leak into the urine, leading to severe swelling (edema), fatigue, and a high risk of blood clots. For patients, the diagnosis marks the beginning of an uncertain and often frightening journey.

An estimated 96,000 people in the United States and 88,000 in the European Union live with the disease. For many, the prognosis is grim. Despite current interventions, up to 30% of patients see their condition progress to end-stage kidney failure within a decade, a devastating outcome that necessitates life-altering dialysis or a kidney transplant.

“We are managing a chronic fire with tools that can sometimes cause as much damage as the fire itself,” explained one leading nephrologist not involved in the study. “The older alkylating agents can have serious long-term risks, including cancer and infertility. The calcineurin inhibitors like tacrolimus are effective for some, but many patients relapse the moment you stop the drug, and long-term use carries a risk of kidney toxicity—the very organ we are trying to save.”

This gap in care has created a significant unmet need for a therapy that can not only induce remission but sustain it safely, preserving kidney function and allowing patients to reclaim their quality of life.

A New Therapeutic Contender Emerges

The MAJESTY study was designed to address this need head-on. As the first global Phase III trial in PMN, it enrolled 142 adults and randomized them to receive either Gazyva/Gazyvaro or tacrolimus. The primary endpoint was stringent: the percentage of patients achieving complete remission—a state where proteinuria drops to normal levels, indicating the autoimmune attack has ceased—at the two-year mark.

Gazyva/Gazyvaro works by targeting CD20, a protein on the surface of B cells. These immune cells are responsible for producing the harmful autoantibodies that attack the kidneys in PMN. By depleting these B cells, the drug strikes at the root cause of the disease. While another anti-CD20 antibody, rituximab, is already used off-label with success in PMN, Gazyva/Gazyvaro is a next-generation, glycoengineered antibody designed for deeper and more potent B cell depletion.

The trial’s success in showing superiority over a widely used CNI is a critical development. Key secondary endpoints further bolstered the findings, showing statistically significant benefits for Gazyva/Gazyvaro in achieving overall remission (both complete and partial) at two years and complete remission at an earlier timepoint of 76 weeks. Importantly, Roche reported that the drug's safety profile was consistent with its known effects, with no new warning signals identified.

Reshaping the Treatment Landscape and Healthcare Economics

The potential approval of Gazyva/Gazyvaro would not just add another drug to the formulary; it could fundamentally reshape the treatment paradigm for PMN. Having a therapy specifically studied and indicated for the disease provides a level of evidence and regulatory backing that is currently absent. This can streamline treatment decisions for clinicians and improve access for patients.

Furthermore, the economic implications are substantial. The costs associated with managing end-stage kidney disease are immense, placing a heavy burden on patients, families, and the healthcare system. A single year of hemodialysis can cost upwards of $90,000 per patient, while a kidney transplant involves massive upfront surgical costs and a lifetime of follow-up care and immunosuppression.

By effectively inducing and maintaining complete remission, a therapy like Gazyva/Gazyvaro holds the potential for significant long-term cost savings. Preventing even a fraction of the 30% of patients who progress to kidney failure could translate into billions of dollars saved in downstream medical expenses, shifting the focus from managing complications to preventing them.

A Strategic Pillar in Roche’s Immunology Empire

For Roche, this success is far more than a single trial win. It is a crucial validation of its broader immunology strategy and a demonstration of its ability to maximize the value of its key assets. Gazyva/Gazyvaro is already a blockbuster drug in oncology and has been steadily building a second life as an immunology powerhouse.

This marks the fourth positive Phase III study for the drug in immune-mediated diseases, following successful readouts in lupus nephritis (for which it is already approved), systemic lupus erythematosus, and idiopathic nephrotic syndrome. This string of victories solidifies Roche’s growing dominance in the lucrative and complex field of autoimmune disorders, particularly those affecting the kidney.

With the positive MAJESTY data in hand, Roche plans to submit its findings to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Given the unmet need and the rare nature of the disease, the drug could be eligible for expedited review pathways, potentially shortening the timeline to approval. If all goes smoothly, Gazyva/Gazyvaro could be available to PMN patients as an approved therapy within the next 12 to 18 months, heralding a new and more hopeful era for a community long in waiting.